Singapore Group Will Develop 'Most Promising' Ebola Vaccine
The rVSV Bundibugyo candidate is designed to stay stable in standard refrigerators and could be easier to deploy in remote outbreak areas, officials said.
6 Articles
6 Articles
WHO points out the most promising vaccine against Ebola; human tests will be developed in Singapore Adobe Stock The vaccine described by the World Health Organization (WHO) as "the most promising" against Ebola, whose epidemic continues to reach the Democratic Republic of the Congo (DRC), will be developed by a laboratory in Singapore. The announcement was made by Hilleman Laboratories on Thursday (30). More than 1.3 thousand people have died in…
Ebola Bundibugyo: a vaccine candidate enters the production phase for clinical trials Image media Patient Fri 31/07/2026 - 00:12 Corps The Coalition for Innovations in Epidemiology Preparedness (CEPI) announced on Thursday a partnership with Hilleman Laboratories to accelerate the development and manufacture of doses of a vaccine candidate against Ebola Bundibugyo virus for clinical trials, while
Singapore-based Hilleman Laboratories is working to create a vaccine against the Bundibugyo strain of Ebola, which has caused more than 1,500 deaths in the Democratic Republic of Congo and Uganda. In response to the situation, the World Health Organization (WHO) has increased alerts and efforts to accelerate vaccine development. The company announced that the vaccine will enter clinical trials and, should it demonstrate safety and efficacy and r…
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
